The Food and Drug Administration (FDA) has authorized a monoclonal antibody cocktail as a measure to prevent infection in some groups of people who were exposed to the CCP virus, the pathogen that causes COVID-19.
The FDA on Friday announced that it had revised its emergency use authorization (EUA) for REGEN-COV, a treatment consisting of jointly administered casirivimab and imdevimab, expanding its use beyond just the treatment of patients who test positive for the virus.
